Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).

@article{Takabatake2007TumorIE,
  title={Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).},
  author={Daisuke Takabatake and Takeo Fujita and Tadahiko Shien and Kensuke Kawasaki and Naruto Taira and Seiji Yoshitomi and Hirotoshi Takahashi and Yoichi Ishibe and Yutaka Ogasawara and Hiroyoshi Doihara},
  journal={International journal of cancer},
  year={2007},
  volume={120 1},
  pages={181-8}
}
Some kinds of breast cancer cell lines, similar to several types of solid tumors, express epidermal growth factor receptor (EGFR). However, gefitinib, an EGFR tyrosine kinase inhibitor, is not effective for all these cell lines. Similarly, taxane is effective for many of the cell lines, although some, such as the multidrug-resistant MCF7/ADR cell line, show taxane-resistance. Here, we examined the growth inhibitory effect of combination treatment with gefitinib and taxane on the breast cancer… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway

Journal of cellular and molecular medicine • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…